Navigation Links
Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
Date:9/5/2011

AMSTERDAM, September 6, 2011 /PRNewswire/ --


Gains US Patent Protection for Proprietary AAV Intellectual Property

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it has entered into an exclusive license agreement with the US National Institutes of Health (NIH) for use of adeno-associated virus serotype 5 (AAV5)-based gene therapy vectors for liver and brain indications. This agreement expands on an original non-exclusive license for AAV5 from the NIH. Financial details of the agreement have not been disclosed.

Concurrent with the signing of this exclusive license, AMT has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for its patent application entitled "AAV vectors produced in insect cells", which covers a core asset of the Company's proprietary manufacturing technology. This patent comprises a novel and significantly improved method of delivery of therapeutic genes to targets using adeno-associated viral (AAV) derived vectors produced in insect cells. The technology has already been successfully applied to Glybera®, a gene therapy for lipoprotein lipase deficiency (LPLD). AMT believes this intellectual property together with the NIH exclusive license places the Company in a unique position for a number of AAV serotype 5-based programs, including hemophilia, acute intermittent prophyria, GDNF-related diseases and Sanfilippo B.

"This expansion of our existing AAV5 license with NIH is an important addition to our intellectual property position as it supports several of our pipeline products that follow Glybera. The granting of an exclusive license by the NIH is very unusual and we believe acknowledges AMT's status in the gene therapy sector," stated Jörn Aldag, CEO of AMT. "As well as continuing to work diligently towards the re-examination of Glybera registration dossier, we also appreciate the significant valu
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
11. Molecular sleuths track evolution through the ribosome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 2015 Empowering biomedical researchers with ... Cubresa Inc. today announced its MR Compatible Small ... PET Scanner uses silicon photomultiplier detector technology, so ... machines from manufacturers like Bruker and Agilent,” said ... Canada. “This enables simultaneous PET and MRI data ...
(Date:5/27/2015)... NEW YORK , May 27, 2015  US-Australian drug ... NVGN ), announced today that it will present at the ... New York on May 29, 2015. The venue ... Manhattan . The Brain ... biotechnology companies, the pharmaceutical industry and the investment community to ...
(Date:5/26/2015)... May 26, 2015 Regenestem Network ... stem cells clinic in Buenos Aires, Argentina. The clinic ... critical care specialist. Pastrana has assembled a multidisciplinary team ... orthopedics in her state-of-the-art Puerto Madero office. , ... I to phase IV clinical studies in cellular therapies, ...
(Date:5/26/2015)... May 26, 2015  Sangamo BioSciences, Inc. (NASDAQ: SGMO ... and CEO, will provide an update on the progress of ... of the company,s business strategy at 1:30pm ET on Monday, ... The conference is being held in New York, ... live and may be accessed via a link on the ...
Breaking Biology Technology:Cubresa Launches Simultaneous PET/MRI Technology 2Novogen to Present at Brain Tumor Biotech Summit 2015 2Novogen to Present at Brain Tumor Biotech Summit 2015 3Novogen to Present at Brain Tumor Biotech Summit 2015 4Novogen to Present at Brain Tumor Biotech Summit 2015 5Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 2Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 3Sangamo BioSciences Announces Presentation At The Jefferies 2015 Global Healthcare Conference 2
... 2012 Reportlinker.com announces that a ... in its catalogue: , Neuroendocrine ... Market Forecast to 2019 ... Carcinoma Therapeutics - Pipeline Assessment and ...
... Advanced Biofuels, LLC announced today that the United ... Butamax Patent Number 8,178,328. The ,328 patent covers ... from recombinant microorganisms at commercial scale.  These novel ... convert sugar to isobutanol. (Logo: ...
... external bioreactor holding human cells pumped out an anti-inflammatory ... a rat with acute inflammation caused by bacterial products ... from researchers at the University of Pittsburgh School of ... findings were published today in the inaugural issue of ...
Cached Biology Technology:Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 2Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 3Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 4Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 5Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 6Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 7Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 8Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 9Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 10Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol 2Bio-hybrid device acts as 'thermostat' to control systemic inflammation in sepsis 2
(Date:5/18/2015)... , May 18, 2015 Fingerprint Cards ... FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if its ... until and including Q3 2015 and the sensors will be ... Communicated order values for 2015 hereby amount to 740 MSEK ... 2015 of 140 MSEK and a number of smaller orders ...
(Date:5/11/2015)... JOSE, Calif. , May 11, 2015 /PRNewswire/ ... developer of human interface solutions, today announced the ... Vice President and Chief Financial Officer, reporting to ... Ali replaces Synaptics, current Chief Financial Officer, ... December 2014. Mr. Ali brings ...
(Date:5/10/2015)... Fingerprint Cards (FPC) has received an ... the distributor World Peace Industrial Group (WPI), part of WPG ... Asia . Deliveries are planned to take place during ... manufacturers in China . The order value ... of + 1 000 MSEK for 2015.   Jörgen ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
... nutrient-rich, blue-green algae, appeared to provide neuroprotective support ... of amyotrophic lateral sclerosis (ALS), also known as ... have found. Although more research is needed, ... clinical benefits for ALS patients. A spirulina ...
... Boston University School of Medicine (BUSM) have demonstrated that ... to maintain their pro-inflammatory response in people with type ... first time, how a loss in homeostasis in this ... associated with T2D. Barbara Nikolajczyk, PhD, an ...
... The Biophysical Society has announced the winners of its student ... at the Baltimore Convention Center in Baltimore, Maryland, March 5-9, ... on scientific merit, with priority given to those who will ... a travel grant and will be recognized at a reception ...
Cached Biology News:Blue-green algae tested for treating ALS 2Biophysical Society announces winners of 2011 Student Travel Awards 2Biophysical Society announces winners of 2011 Student Travel Awards 3Biophysical Society announces winners of 2011 Student Travel Awards 4Biophysical Society announces winners of 2011 Student Travel Awards 5
... The ELx50 is a fast and versatile ... with our patented Dual-ActionTM 16-channel manifold. This ... the dispense and aspiration manifolds for overfill ... and 384-well formats. The problem of fitting ...
... Schistosomal glutathione-S-transferase (GST) is commonly used as ... E. coli (1). The GSTTag sequence has ... in some cases the solubility of its ... properly folded form, GSTTag fusion proteins can ...
... 1200L sets the new standard for ... incorporating the latest technologies and providing ... analytical needs. The Atmospheric Pressure ... Quadrupole Analyzer provide superior selectivity and ...
Polio component type I...
Biology Products: